Clinical Trials Logo

Advanced/Metastatic Solid Tumors clinical trials

View clinical trials related to Advanced/Metastatic Solid Tumors.

Filter by:

NCT ID: NCT05718895 Recruiting - Clinical trials for Advanced/Metastatic Solid Tumors

A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors

CLINCH
Start date: March 27, 2023
Phase: Phase 1
Study type: Interventional

This is an Open, Multi-center, Phase I Clinical Study of ATG 022 in Patients with Advanced/metastatic Solid Tumors

NCT ID: NCT05614258 Recruiting - Clinical trials for Advanced/Metastatic Solid Tumors

Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors

Start date: February 13, 2023
Phase: Phase 1
Study type: Interventional

ADG206 is an activatable prodrug form of a fully human monoclonal antibody (mAb) of the immunoglobulin G1 (IgG1) subclass that specifically targets cluster of differentiation 137 (CD137) (also known as 4-1BB) as a co-stimulatory receptor agonist for the treatment of advanced malignancies.

NCT ID: NCT05607498 Recruiting - Clinical trials for Advanced/Metastatic Solid Tumors

First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma

Start date: March 1, 2023
Phase: Phase 1
Study type: Interventional

For solid tumors and lymphoma, respectively: This study is to evaluate the safety and tolerability of EMB-07 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). Pharmacokinetics (PK), immunogenicity, and the anti-multiple myeloma activity of EMB-07 will also be assessed.

NCT ID: NCT05514444 Recruiting - Neoplasms Clinical Trials

Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)

Start date: September 25, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of MK-4464 as monotherapy and in combination with pembrolizumab in participants with advanced/metastatic solid tumors.

NCT ID: NCT05405595 Recruiting - Clinical trials for Advanced/Metastatic Solid Tumors

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Start date: June 15, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1b/2, open-label, dose escalation study to evaluate the safety, tolerability, PK, and immunogenicity of ADG126-pembrolizumab combination regimens in patients with advanced/metastatic solid tumors.

NCT ID: NCT05394168 Active, not recruiting - Clinical trials for Advanced/Metastatic Solid Tumors

A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors

Start date: December 9, 2022
Phase: Phase 1
Study type: Interventional

This phase I, first-in-human, open-label clinical study will evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of HLX53 (an anti-TIGIT Fc fusion protein) in patients with advanced/metastatic solid tumors.

NCT ID: NCT05277402 Completed - Clinical trials for Advanced/Metastatic Solid Tumors

ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Start date: February 9, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1b, open-label, dose escalation study to evaluate the safety, tolerability, PK, and immunogenicity of an ADG116-pembrolizumab combination regimen in patients with advanced/metastatic solid tumors. Study drug ADG116, is an anti -CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4. Pembrolizumab is a PD-1 receptor-blocking antibody (a humanized IgG4 monoclonal antibody) which is indicated for the treatment of patients across a number of indications. The treatment strategy of using anti-PD 1 therapy combined with anti-CTLA-4 therapy is to explore the potential of combination checkpoint inhibition regimens for the enhanced antitumor efficacy results.

NCT ID: NCT04645069 Recruiting - Clinical trials for Advanced/Metastatic Solid Tumors

ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors

Start date: March 15, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

ADG126, ADG126 in Combination with anti-PD1 antibody, and ADG126 in Combination with ADG106 in Patients with Advanced/Metastatic Solid Tumors .

NCT ID: NCT04501276 Active, not recruiting - Clinical trials for Advanced/Metastatic Solid Tumors

A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients

Start date: September 23, 2020
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, dose escalation study in patients with advanced/metastatic solid tumors. Study drug, ADG116, is an anti -CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4. ADG106, a fully human ligand-blocking agonistic anti-CD137 IgG4 mAb, is expected to enhance the activity of activated T cells. The enhanced antitumor efficacy results observed from the preclinical studies of ADG116 in combination with ADG106 or anti-PD-1 provided further support to explore such combinations in clinical settings for better patient responses.

NCT ID: NCT04182516 Active, not recruiting - Clinical trials for Advanced/Metastatic Solid Tumors

Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors

Start date: November 25, 2019
Phase: Phase 1
Study type: Interventional

Phase I, first-in-human, open-label, multicenter, dose-escalation and dose expansion study with the aim of exploring safety, tolerability and preliminary antitumor activity of NMS-03305293 (a PARP inhibitor) as single agent in adult patients with selected advanced/metastatic, relapsed/refractory solid tumors who have exhausted standard treatment options or for whom standard therapy is considered unsuitable.